Printer Friendly

ALLERGAN REPORTS DIVIDEND AT ANNUAL SHAREHOLDERS MEETING; COMPANY FOCUSED ON CORE BUSINESSES

 ALLERGAN REPORTS DIVIDEND AT ANNUAL SHAREHOLDERS MEETING;
 COMPANY FOCUSED ON CORE BUSINESSES
 IRVINE, Calif, April 28 /PRNewswire/ -- Allergan (NYSE: AGN) announced today a first quarter dividend of $0.09 per share, payable June 16, 1992, to stockholders of record on May 26, 1992.
 "The significant changes Allergan underwent in 1991 have allowed our team to concentrate their activities on our customers and controlling costs," said William C. Shepherd, President and Chief Executive Officer, speaking to shareholders at the Irvine Marriott Hotel. "Our focus is on maintaining our leadership position in eye care, expanding our skin care business, pursuing opportunities in adjacent markets, and investing in our novel technologies--Oculinum(R)/Botox(TM) and receptor- selective retinoids."
 As part of the meeting's business, shareholders reelected four directors: Allergan Chairman, Gavin Herbert; Handel E. Evans, executive chairman, Walsh International Inc.; Leslie G. McCraw, Chairman of the Board and CEO, Fluor Corporation; and Henry Wendt, Chairman of the Board, SmithKline Beecham p.l.c.
 A proposal by the American Baptist Home Mission Society and the Ministers and Missionaries Benefit Board of American Baptist Churches for Allergan to withdraw its presence in South Africa was rejected by shareholders.
 In stating Allergan's South Africa position, Herbert said, "Our position in South Africa can be misunderstood by those who believe the only way to work for political change in South Africa is through withdrawal by U.S. companies and the severing of economic ties. We believe our presence there is positive--allowing us to lend our support to initiatives to improve employment, education, and housing for blacks, and, as a health care company, we feel it is our responsibility to provide our health care products to all who need them."
 Shareholders also voted to approve a proposal amending the 1989 Incentive Compensation Plan. That amendment changes the maximum number of shares issuable under the Incentive Plan from 5,000,000 shares to an annual maximum of 1.5 percent of outstanding Common Stock.
 In his remarks, Shepherd emphasized Allergan's commitment to research and development. "Our cost reductions through plant consolidations and G&A (general and administrative) streamlining programs enable us to redeploy some of that spending into R&D and other opportunities. These cost containment measures and increased investment in new technology are generating the expected favorable impact." During the first quarter of 1992, Allergan increased its R&D investments by 14 percent.
 Research Pipeline Review
 Oculinum(R)/Botox(TM) (botulinum toxin type A) is currently awaiting FDA approval for cervical dystonia, and it is now undergoing Phase III clinical trials in juvenile cerebral palsy and Phase II trials in essential tremor.
 Oflox(R)/Exocin(R) solution, a topical anti- infective drug for treating bacterial conjunctivitis and bacterial corneal ulcers, is currently awaiting FDA approval. It is currently being marketed in France and Italy.
 Acular(R) solution, ophthalmic ketorolac used to treat postoperative inflammation and itching associated with allergic conjunctivitis, is awaiting FDA approval. It has been approved for marketing in Canada, New Zealand, and the Netherlands.
 Topical Retinoid (AGN190168), an Allergan developed and patented compound, is currently undergoing clinical tests since the fourth quarter for psoriasis and acne.
 An Azelaic Acid product (AGN191861) for acne was acquired last year from Schering A.G. It was launched successfully in Europe and has been filed for approval in Canada and is in Phase III clinical trials in the U.S.
 Complete(TM), Allergan's one-bottle contact lens disinfection system, is pending FDA approval.
 Allergan, Inc., headquartered in Irvine, California, is a global provider of specialty therapeutic products; is expanding beyond skin care and its leadership position in eye care into adjacent markets; and is pursuing other core technologies.
 -0- 4/28/92
 /CONTACT: Shel Holtz (media), 714-752-4387 or 818-366-5296 (home), or Jeff D'Eliscu (investors), 714-752-4636 or 714-675-9475 (home), both of Allergan/
 (AGN) CO: Allergan, Inc. ST: California IN: MTC SU: DIV


CH -- LA029 -- 3850 04/28/92 13:17 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 28, 1992
Words:650
Previous Article:UGI BOARD DECLARES HIGHER COMMON DIVIDEND; UTILITIES UNIT DECLARES PREFERRED PAYOUTS
Next Article:CARETENDERS HEALTHCORP ANNOUNCES TWO ACQUISITIONS


Related Articles
ALLERGAN SKIN CARE DIVISION WILL REPORT TO HAUGEN; W. RICHARD ULMER TO LEAVE ALLERGAN
ALLERGAN INCREASES SECOND QUARTER DIVIDEND; BOARD APPROVES ADDITIONAL STOCK REPURCHASE
HARRIS OUTLINES STRATEGY FOR SUSTAINED GROWTH
CHAIRMAN CITES COMPANY'S 'WINNING PARTNERSHIPS,' STEADY GROWTH AND STRATEGIC INITIATIVES AT SECURITY-CONNECTICUT ANNUAL MEETING
DCR Assigns Allergan A+/D-1 Ratings
AEGON N.V. - AEGON's financial calendar for 2007 and 2008.
AEGON's Financial Calendar for 2007 and 2008.
AEGON's Financial Calendar for 2007 and 2008.
CORE VCT II PLC - AGM Statement and Interim Dividend.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters